Natera Announces Prospective Randomized Clinical Trial with Signatera™
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, today announced that its Signatera molecular residual disease (MRD) test will be used in the DARE study, a multi-center clinical trial of palbociclib (IBRANCE®), a CDK4/6 inhibitor developed by Pfizer for the treatment of HR-positive, HER2-negative advanced breast cancer when given in combination with an aromatase […]